SOLVE FSHD Invests in Epic Bio to Advance Potentially Curative Therapy
– Investment will advance Epic’s lead program, EPI-321, toward clinic in 2024 – SOUTH SAN…
ISP
SOLVE FSHD Invests in Epic Bio to Advance Potentially Curative Therapy
– Investment will advance Epic’s lead program, EPI-321, toward clinic in 2024 – SOUTH SAN…
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1…
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1…
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
Improved ADCC with ADAM17 gene knockout of NK or CAR NK cells, supporting ADAM17 KO…
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the…
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the…
2023 NAB Show®: Kalray Unveils ngenea®2, A Major Evolution of Its Open Data Management Platform, and Demonstrates It With AWS and Seagate
ngenea®2, combined with Kalray’s software-defined storage solution (pixstor) and Kalray’s processors (Coolidge), opens new horizons…
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
Elliott Levy, M.D. Editas Medicine announced the appointment of Elliott Levy, M.D., to its Board…
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
Elliott Levy, M.D. Editas Medicine announced the appointment of Elliott Levy, M.D., to its Board…
Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential…
Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential…
TransCode Therapeutics to present at AACR Annual Meeting 2023
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology…
SparingVision appoints Joseph C. Papa as Chairman
SparingVision appoints Joseph C. Papa as Chairman Former Bausch and Lomb Chairman and CEO joins…
SparingVision appoints Joseph C. Papa as Chairman
SparingVision appoints Joseph C. Papa as Chairman Former Bausch and Lomb Chairman and CEO joins…
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
BOSTON, April 05, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology…
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
BOSTON, April 05, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology…
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology…
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
BOSTON, April 03, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an…
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
BOSTON, April 03, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an…